Harry E. Hynes

2.5k total citations
34 papers, 1.9k citations indexed

About

Harry E. Hynes is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Harry E. Hynes has authored 34 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Hematology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Harry E. Hynes's work include Cancer Treatment and Pharmacology (9 papers), Acute Myeloid Leukemia Research (8 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Harry E. Hynes is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Acute Myeloid Leukemia Research (8 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Harry E. Hynes collaborates with scholars based in United States. Harry E. Hynes's co-authors include Kenneth J. Kopecky, Frederick R. Appelbaum, David R. Head, Jeffrey J. Kirshner, Cheryl L. Willman, Patrick J. Flynn, Gary R. Morrow, Joseph A. Roscoe, Richard F. Raubertas and Richard J. Rosenbluth and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Harry E. Hynes

34 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Harry E. Hynes United States	17	974	550	435	399	210	34	1.9k
Clara Chen United States	24	832 0.9×	227 0.4×	604 1.4×	401 1.0×	182 0.9×	101	2.6k
E. Terzoli Italy	29	1.9k 1.9×	366 0.7×	342 0.8×	644 1.6×	161 0.8×	102	2.8k
John C. Michalak United States	19	1.0k 1.1×	131 0.2×	278 0.6×	367 0.9×	85 0.4×	24	1.9k
Αngelos Koutras Greece	28	1.6k 1.7×	283 0.5×	588 1.4×	543 1.4×	88 0.4×	132	2.5k
Jamie L. Renbarger United States	20	806 0.8×	238 0.4×	507 1.2×	235 0.6×	272 1.3×	65	1.8k
Kara L. Cushing‐Haugen United States	25	511 0.5×	165 0.3×	496 1.1×	113 0.3×	381 1.8×	59	2.5k
Fiorina Casale Italy	29	362 0.4×	281 0.5×	906 2.1×	340 0.9×	354 1.7×	95	2.3k
Adnan Aydıner Türkiye	25	1.0k 1.1×	90 0.2×	304 0.7×	473 1.2×	185 0.9×	156	2.3k
Paul Gilman United States	14	1.1k 1.1×	207 0.4×	197 0.5×	273 0.7×	119 0.6×	37	1.8k
Ursula Amstutz Switzerland	24	948 1.0×	103 0.2×	603 1.4×	187 0.5×	105 0.5×	50	2.1k

Countries citing papers authored by Harry E. Hynes

Since Specialization

Citations

This map shows the geographic impact of Harry E. Hynes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry E. Hynes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry E. Hynes more than expected).

Fields of papers citing papers by Harry E. Hynes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry E. Hynes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry E. Hynes. The network helps show where Harry E. Hynes may publish in the future.

Co-authorship network of co-authors of Harry E. Hynes

This figure shows the co-authorship network connecting the top 25 collaborators of Harry E. Hynes. A scholar is included among the top collaborators of Harry E. Hynes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry E. Hynes. Harry E. Hynes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Loesch, David, Lina Asmar, Gregory A. Parker, et al.. (2003). A phase II Trial of Weekly Paclitaxel, 5-Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Breast Cancer. Breast Cancer Research and Treatment. 77(2). 115–123. 2 indexed citations

Morrow, Gary R., Jane T. Hickok, Joseph A. Roscoe, et al.. (2003). Differential Effects of Paroxetine on Fatigue and Depression: A Randomized, Double-Blind Trial From the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology. 21(24). 4635–4641. 229 indexed citations

Glaspy, John A., Glen R. Justice, J. Keßler, et al.. (2001). A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. British Journal of Cancer. 84(s1). 17–23. 62 indexed citations

Pandya, Kishan J., Richard F. Raubertas, Patrick J. Flynn, et al.. (2000). Oral Clonidine in Postmenopausal Patients with Breast Cancer Experiencing Tamoxifen-Induced Hot Flashes: A University of Rochester Cancer Center Community Clinical Oncology Program Study. Annals of Internal Medicine. 132(10). 788–793. 209 indexed citations

Grunberg, Steven M., John Crowley, Kenneth R. Hande, et al.. (1999). Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemotherapy and Pharmacology. 44(6). 461–468. 15 indexed citations

Karanes, Chatchada, Kenneth J. Kopecky, David R. Head, et al.. (1999). A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia. Leukemia Research. 23(9). 787–794. 64 indexed citations

Russell, Christy, Joe M. O’Sullivan, Harry E. Hynes, et al.. (1997). Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.. Journal of Clinical Oncology. 15(7). 2494–2501. 14 indexed citations

Morrow, Gary R., et al.. (1997). Progress in reducing anticipatory nausea and vomiting: a study of community practice. Supportive Care in Cancer. 6(1). 46–50. 46 indexed citations

Meyskens, Frank L., Kenneth J. Kopecky, Frederick R. Appelbaum, et al.. (1995). Effects of vitamin a on survival in patients with chronic myelogenous leukemia: A SWOG randomized trial. Leukemia Research. 19(9). 605–612. 23 indexed citations

10.

Green, Stephanie, et al.. (1994). Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. Investigational New Drugs. 12(2). 129–132. 5 indexed citations

11.

Murphy, William K., Frank V. Fossella, R Winn, et al.. (1993). Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 85(5). 384–388. 373 indexed citations

12.

Fletcher, William S., Danni Daniels, Vernon K. Sondak, et al.. (1993). Evaluation of Cisplatin and DTIC in Inoperable Stage III and IV Melanoma. American Journal of Clinical Oncology. 16(4). 359–362. 24 indexed citations

13.

Marshall, M. Ernest, Michael Wolf, E. David Crawford, et al.. (1993). Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. Investigational New Drugs. 11(2-3). 207–209. 21 indexed citations

14.

Ryan, Donna H., Kenneth J. Kopecky, David Head, et al.. (1992). Analysis of Treatment Failure in Acute Nonlymphocytic Leukemia Patients over Fifty Years of Age. American Journal of Clinical Oncology. 15(1). 69–75. 14 indexed citations

15.

Gallion, Holly H., Pengfei Liu, Janet OʼSullivan, et al.. (1992). Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: A Southwest Oncology Group study☆☆☆. Gynecologic Oncology. 46(2). 230–232. 5 indexed citations

16.

Taylor, Sarah A., et al.. (1991). Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial.. Journal of Clinical Oncology. 9(8). 1476–1479. 20 indexed citations

17.

Taylor, Sarah A., John Crowley, F. Stephen Vogel, et al.. (1991). Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. Investigational New Drugs. 9(2). 195–197. 7 indexed citations

18.

Rivkin, Saul E., et al.. (1990). 5-Day vinblastine infusion for pancreatic adenocarcinoma. Investigational New Drugs. 8(2). 205–206. 1 indexed citations

19.

Thigpen, J.T., Harry E. Hynes, William A. Nahhas, et al.. (1987). A Phase II Trial of Vinblastine in Patients with Advanced or Recurrent Endometrial Carcinoma A Southwest Oncology Group Study. American Journal of Clinical Oncology. 10(5). 429–431. 6 indexed citations

20.

Martino, Silvana, David A. Decker, Harry E. Hynes, & Cynthia Kresge. (1987). Phase II evaluation of Aclacinomycin-A in advanced ovarian carcinoma. Investigational New Drugs. 5(4). 373–374. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact